MeiraGTx scores $400M from Oberland Capital to help get 2 gene therapies to commercialization
MeiraGTx has secured up to $425 million in new funding pathways to advance two gene therapies toward commercialization.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
MeiraGTx has obtained a cash infusion from Oberland Capital. The funding includes up to $375 million in royalty financing and $10 million in equity, with some coverage totaling the new funding pathways at $425 million. The capital is intended to help bring two gene therapies to market and has been used to retire Perceptive debt.
Coverage from Fierce Biotech, TradingView, and Seeking Alpha emphasizes the role of Oberland Capital in this financing. Additionally, SimplyWall.st reports that MeiraGTx stock rose 8.5% following the news, while H.C. Wainwright reiterated its stock rating for the company.
Future catalysts include the BLA filing for AAV2-hAQP1 regarding xerostomia, which is expected in the first half of 2027. Other developments to monitor include the Bota-Vec acquisition and Q2 207 data.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 1h ago.
Quick answers
Who provided the funding for MeiraGTx?
The funding was provided by Oberland Capital.
What is the purpose of the new capital?
The funds are intended to help get two gene therapies to commercialization and were used to retire Perceptive debt.
When is the BLA filing for AAV2-hAQP1 expected?
According to Seeking Alpha, the BLA filing is expected in the first half of 2027.
Coverage (5)
- MeiraGTx Secures Up To $375 Million Royalty Financing, Adds $10 Million Equity, Retires Perceptive Debt TradingView · 1d ago
- Exclusive BAC Article: MeiraGTx; AAV2-hAQP1 Q2 207 Data Xerostomia, BLA Filing 1st Half 2027, Bota-Vec Acquisition, Oberland Capital Cash Infusion, And Catalysts (NASDAQ:MGTX) Seeking Alpha · 1d ago
- MeiraGTx Holdings (MGTX) Is Up 8.5% After Securing US$425M In New Funding Pathways simplywall.st · 1d ago
- H.C. Wainwright reiterates MeiraGTx stock rating on financing deal Investing.com · 1d ago
- MeiraGTx scores $400M from Oberland Capital to help get 2 gene therapies to commercialization Fierce Biotech · 1d ago
Topics
Related trends
Company Plans to Drop 600,000 Bacteria-Infected Mosquitoes into DC This Summer
A biotechnology project aims to release bacteria-infected mosquitoes in the DC region to combat disease.
FDA’s top gene therapy regulator is leaving his role
The FDA's top gene therapy regulator is stepping down, amid a significant setback for a kidney disease drug.
Louisiana Notches a Sickle Cell First
A Louisiana man is the first in the state to be functionally cured of sickle cell disease.
ROBERT F. KENNEDY JR.: The future of medicine should be built in America
Robert F. Kennedy Jr. and other commentators are highlighting the strategic competition between the U.S. and China over the future of biotechnology.
Exclusive | FDA Will Reverse Rejection of Third Rare-Disease Drug, Regenxbio Says
The FDA is reversing its rejection of Regenxbio's gene therapy for Hunter syndrome, marking the third such reversal for rare-disease drugs.
Scientists test first-ever therapy to make human cells young again
Human trials have officially commenced for the first-ever gene therapy designed to rejuvenate human cells and reverse aging.